

2007

Functional Interplay Between the B-box 2 and the B30.2 (SPRY) Domains of TRIM5 α

Xi Ling

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA

Byeongwoon Song

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA

Shi-Hua Xiang

University of Nebraska-Lincoln, sxiang2@unl.edu

Joseph Sodroski

Harvard Medical School, fdajiop@gmail.com

Follow this and additional works at: <http://digitalcommons.unl.edu/virologypub>



Part of the [Biological Phenomena, Cell Phenomena, and Immunity Commons](#), [Cell and Developmental Biology Commons](#), [Genetics and Genomics Commons](#), [Infectious Disease Commons](#), [Medical Immunology Commons](#), [Medical Pathology Commons](#), and the [Virology Commons](#)

Ling, Xi; Song, Byeongwoon; Xiang, Shi-Hua; and Sodroski, Joseph, "Functional Interplay Between the B-box 2 and the B30.2 (SPRY) Domains of TRIM5 α " (2007). *Virology Papers*. 293.

<http://digitalcommons.unl.edu/virologypub/293>

This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Published in final edited form as:

Virology. 2007 September 30; 366(2): 234–244.

Functional Interplay Between the B-box 2 and the B30.2(SPRY) Domains of TRIM5 α

Xing Li^a, Byeongwoon Song^a, Shi-Hua Xiang^a, and Joseph Sodroski^{a,b,*}

^a*Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA 02115*

^b*Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115*

Abstract

The retroviral restriction factors, TRIM5 α and TRIMCyp, consist of RING and B-box 2 domains separated by a coiled coil from carboxy-terminal domains. These carboxy-terminal domains (the B30.2(SPRY) domain in TRIM5 α and the cyclophilin A domain in TRIMCyp) recognize the retroviral capsid. Here we show that some B-box 2 changes in TRIM5 α , but not in TRIMCyp, resulted in decreased human immunodeficiency virus (HIV-1) capsid binding. The phenotypic effects of these B-box 2 changes on the restriction of retroviral infection depended on the potency of restriction and the affinity of the TRIM5 α interaction with the viral capsid, two properties specified by the B30.2 (SPRY) domain. Thus, some alterations in the TRIM5 α B-box 2 domain apparently affect the orientation or conformation of the B30.2(SPRY) domain, influencing capsid recognition.

Keywords

retrovirus; restriction factor; TRIMCyp; cyclophilin; trimer; B-box 2; B30.2(SPRY); HIV-1; N-MLV

Introduction

Retroviruses encounter potent blocks to infection in certain mammalian species. In many cases, the restriction is mediated by dominant host factors, such as Fv1 (Best et al., 1996; Hartley, Rowe, and Huebner, 1970; Lilly, 1967; Lilly, 1970), APOBEC3G (Sheehy et al., 2002) and TRIM5 α (Stremlau et al., 2004). TRIM5 α blocks retroviral infection at an early post-entry step in a species-specific manner. Rhesus monkey TRIM5 α (TRIM5 α_{rh}) potently blocks the infection of human immunodeficiency virus-1 (HIV-1) and a range of other retroviruses; by contrast, human TRIM5 α (TRIM5 α_{hu}) modestly restricts HIV-1 infection and potently blocks infection by N-tropic murine leukemia viruses (N-MLV) (Hatzioannou et al., 2004; Keckesova, Ylinen, and Towers, 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al., 2004). The mechanism by which TRIM5 α blocks retroviral infection has not been clearly defined. Previous studies demonstrated that TRIM5 α proteins specifically recognize the viral cores and accelerate the uncoating process (Li et al., 2006c; Perron et al., 2006; Sebastian and

*Corresponding author: Joseph G. Sodroski, M.D. Dana-Farber Cancer Institute 44 Binney Street - JFB 824 Boston, MA 02115 Phone: (617) 632-3371 Fax: (617) 632-4338 Email: joseph_sodroski@dfci.harvard.edu

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Luban, 2005; Stremlau et al., 2006), thus potentially interfering with the orderly disassembly of the viral capsid (Forshey et al., 2002).

TRIM5 α is a member of the large tripartite motif (TRIM) protein family (Reymond et al., 2001). TRIM proteins contain RING, B-box 2 and coiled-coil domains; many cytoplasmic TRIM proteins, like TRIM5 α , also contain a B30.2(SPRY) domain (Meroni and Diez-Roux, 2005; Reymond et al., 2001). The B30.2(SPRY) domain of TRIM5 α determines viral specificity and potency of restriction by modulating recognition of the retroviral capsid (Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005; Perez-Caballero et al., 2005a; Li et al., 2006c). For example, in an *in vitro* binding assay, the B30.2(SPRY) domain was shown to be the major determinant of the association of TRIM5 α_{rh} with the assembled HIV-1 capsid-nucleocapsid (CA-NC) complex (Li et al., 2006c; Stremlau et al., 2006).

The role of TRIM5 α domains other than the B30.2(SPRY) domain in antiretroviral activity has been investigated. The RING finger domain is the signature of a class of E3 ubiquitin ligases involved in proteasome-mediated protein degradation (Meroni and Diez-Roux, 2005). Indeed, some TRIM proteins have been shown to exhibit ubiquitin ligase activity and modify their target proteins with ubiquitin (Dupont et al., 2005; Horn et al., 2004; Meroni and Diez-Roux, 2005; Trockenbacher et al., 2001; Xu et al., 2003). However, deletion of the TRIM5 α RING domain only partially attenuated antiviral activity (Javanbakht et al., 2005; Perez-Caballero et al., 2005a; Stremlau et al., 2004). Moreover, TRIM5 α -mediated restriction activity was not affected by modulation of E1 ubiquitin ligase activity in a temperature-dependent cell line (Perez-Caballero et al., 2005b). Finally, proteasome inhibitors did not impair the restriction activity of TRIM5 α (Perez-Caballero et al., 2005b; Stremlau et al., 2006; Anderson et al., 2006; Wu et al., 2006). Proteasome inhibitors can rescue viral reverse transcription from the TRIM5 α -mediated restriction, but the mechanistic basis for this phenomenon is unknown (Anderson et al., 2006; Wu et al., 2006). The B-box 2 domain plays an important but poorly understood role in the function of TRIM proteins (Meroni and Diez-Roux, 2005; Reymond et al., 2001). Deletion of the B-box 2 domain of TRIM5 α eliminated its antiretroviral activities (Javanbakht et al., 2005; Perez-Caballero et al., 2005a). It has been suggested that the RING and B-box 2 domains may specify an “effector” function, either by recruiting an additional co-factor or by participating in particular types of self-association (Diaz-Griffero et al., 2006b; Perez-Caballero et al., 2005a; Stremlau et al., 2006). The coiled-coil domain is known to be essential for both homomultimerization and heteromultimerization of many TRIM proteins (Cao et al., 1997; Javanbakht et al., 2006; Mische et al., 2005; Perez-Caballero et al., 2005a; Reymond et al., 2001). TRIM5 α trimerization, which depends on the coiled coil and the L2 linker region connecting the coiled-coil and B30.2 domains, contributes greatly to the avidity for the retroviral capsid and the restriction of viral infection (Javanbakht et al., 2006).

In this study, we altered a combination of residues in the B-box 2 domain of wild-type human and rhesus monkey TRIM5 α , as well as chimeric and mutant TRIM5 α proteins, and examined the effects of these changes on antiretroviral activity against human immunodeficiency virus-1 (HIV-1), N-tropic Moloney leukemia virus (N-MLV) and simian immunodeficiency virus (SIV_{mac}). The results show that, depending on the restriction potency of the parental proteins, a property determined by the B30.2(SPRY) domain, the same alterations of the B-box 2 domain can confer different phenotypes on retrovirus restriction. Moreover, the B-box 2 alterations used in this study dramatically affected the association of the TRIM5 α proteins with *in vitro* assembled HIV-1 CA-NC complexes, suggesting a functional interplay between the TRIM5 α B-box 2 and the B30.2(SPRY) domains.

Results

Differential effects of TRIM5 α B-box 2 changes on HIV-1 and N-MLV restriction

Despite 87% sequence identity, rhesus monkey TRIM5 α (TRIM5 α_{rh}) and human TRIM5 α (TRIM5 α_{hu}) exhibit differences in the spectrum of restricted retroviruses due to divergence in the B30.2 domains (Perez-Caballero et al., 2005a; Perron, Stremlau, and Sodroski, 2006; Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). TRIM5 α_{rh} more potently restricts HIV-1 infection than TRIM5 α_{hu} , whereas TRIM5 α_{hu} more potently restricts the infection of N-MLV (Hatzioannou et al., 2004; Keckesova, Ylinen, and Towers, 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al., 2004). In a previous study, we generated two B-box 2 mutants of TRIM5 α_{rh} , each with a few amino acid residues changed to that seen in a relatively distant TRIM protein relative, TRIM21 (Li et al., 2006b). The TRIM21 B-box 2 domain, in contrast to B-box 2 domains of close TRIM5 relatives like TRIM6 or TRIM34, does not effectively substitute for that of TRIM5 α_{rh} (Li et al., 2006b). Mutant Cluster I-A exhibits the following changes: Q109E, E110K, V114A, I115L and L118V; Mutant Cluster II-A exhibits the following changes: E120A, R121Q, Q123R and E124K (Figure 1). The wild-type and mutant TRIM5 α_{rh} proteins were expressed in HeLa cells (Figure 2A). Both B-box 2 mutants restricted HIV-1 infection nearly as efficiently as the wild-type TRIM5 α_{rh} protein (Figure 2B). However, no anti-N-MLV activity was detected for either of the mutants. In fact, N-MLV infected cells expressing the Cluster I-A and Cluster II-A TRIM5 α_{rh} mutants more efficiently than cells transduced with the control LPCX vector; these mutants may exert dominant-negative effects on the TRIM5 α_{hu} protein endogenously expressed in the HeLa cells. Thus, the B-box 2 changes confer different phenotypes with respect to the anti-HIV-1 and the anti-N-MLV activities of rhesus monkey TRIM5 α .

To investigate the phenotypes of the B-box 2 mutants in the context of more potent restriction against N-MLV infection, the same changes were introduced into TRIM5 α_{hu} . Interestingly, both TRIM5 α_{hu} mutants retained anti-N-MLV activity, but lost the weak restricting activity against HIV-1 associated with wild-type TRIM5 α_{hu} (Figure 2B). These results demonstrate that changes in the B-box 2 domain of TRIM5 α can affect both HIV-1 and N-MLV restriction. Apparently, if the parental TRIM5 α is a potent restrictor of a specific virus, then the restriction activity directed against that virus can better tolerate the changes introduced into the B-box 2 domain.

The phenotypic effects of the B-box 2 changes are determined by the B30.2(SPRY) domain

The determinants of species-specific differences in the potency of TRIM5 α -mediated restriction to HIV-1 and N-MLV largely reside in the B30.2(SPRY) domain (Perez-Caballero et al., 2005a; Perron, Stremlau, and Sodroski, 2006; Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). The B30.2 domain from TRIM5 α_{rh} is sufficient to confer potent anti-HIV-1 activity on TRIM5 α_{hu} , whereas the B30.2 domain from TRIM5 α_{hu} further increases the anti-N-MLV potency of TRIM5 α_{rh} (Perez-Caballero et al., 2005a; Perron, Stremlau, and Sodroski, 2006; Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). To examine whether the effects of the B-box 2 changes on restriction are influenced by the B30.2(SPRY) domain, the B-box 2 changes were introduced into two previously established chimerae, TRIM5 α R(H286-493) and TRIM5 α H(R286-493) (Stremlau et al., 2005). TRIM5 α R(H286-493) is rhesus monkey TRIM5 α containing a human TRIM5 α B30.2(SPRY) domain; TRIM5 α H(R286-493) is human TRIM5 α with a rhesus monkey TRIM5 α B30.2(SPRY) domain. The residue numbering scheme is based on the human TRIM5 α sequence (Stremlau et al., 2005). The TRIM5 α R(H286-493) and H(R286-493) proteins, with wild-type or mutant B-box 2 domains, were expressed in HeLa cells (Figure 3A). As expected (Stremlau et al., 2005), HeLa cells overexpressing TRIM5 α R(H286-493) were more susceptible to HIV-1 infection than cells expressing wild-type TRIM5 α_{rh} ; however, compared to cells transduced with the empty vector

control (LPCX), the TRIM5 α R(H286-493)-expressing cells still exhibited a strong restriction against HIV-1 infection (Figure 3B). TRIM5 α R(H286-493) restricted N-MLV infection slightly more potently than TRIM5 α_{rh} for the range of viral doses used. Introduction of the Cluster I-A and Cluster II-A changes into the TRIM5 α R(H286-493) protein resulted in restriction phenotypes different from those seen in the TRIM5 α_{rh} background. The TRIM5 α R(H286-493)(I) and TRIM5 α R(H286-493)(II) proteins did not detectably block HIV-1 infection, whereas both mutants were almost as potent as the parent TRIM5 α R(H286-493) protein in restricting N-MLV infection.

As previously reported (Stremlau et al., 2005), human TRIM5 α gained potent restriction activity against HIV-1 upon acquiring the B30.2(SPRY) domain from TRIM5 α_{rh} (see TRIM5 α H(R286-493) in Figure 2B); the N-MLV-blocking activity of this chimera was slightly diminished compared to that of TRIM5 α_{hu} . When the Cluster I-A and Cluster II-A changes were introduced into TRIM5 α H(R286-493), restriction activity against N-MLV was completely lost, whereas the anti-HIV-1 activities of these mutants were maintained (Figure 3B). These results demonstrate that, in the presence of a B30.2(SPRY) domain that specifies a strong restriction against a certain target virus, the effects of the Cluster I-A and Cluster II-A B-box 2 alterations can be functionally tolerated. On the other hand, if the B30.2(SPRY) domain confers relatively weak restricting ability to the TRIM5 α protein, the two sets of B-box 2 alterations completely eliminate detectable antiviral activity.

Effects of B-box 2 alterations on the restriction activities of human TRIM5 α R332P

A single amino acid change (R332P) in the B30.2(SPRY) domain of human TRIM5 α is able to confer potent restricting ability against both HIV-1 and SIV_{mac} infection, even though strong SIV-restricting activity is not a characteristic of either TRIM5 α_{rh} or TRIM5 α_{hu} (Li et al., 2006c; Stremlau et al., 2005; Yap, Nisole, and Stoye, 2005). To examine how changes in the B-box 2 domain affect the multiple restriction activities of TRIM5 α_{hu} R332P, the Cluster I-A and Cluster II-A alterations were combined with the R332P change in human TRIM5 α ; the antiviral activities of these TRIM5 α_{hu} variants were tested in HeLa cells overexpressing these proteins (Figure 4A). The two sets of B-box 2 changes completely abolished the ability of the proteins to block HIV-1 and SIV_{mac} infection (Figure 4B). Interestingly, the Cluster II-A changes also greatly attenuated the ability of TRIM5 α_{hu} R332P to restrict N-MLV infection, whereas the TRIM5 α_{hu} R332P variant with the Cluster I-A changes efficiently blocked N-MLV infection (Figure 4C). Thus, many but not all of the antiviral activities of TRIM5 α_{hu} R332P are sensitive to the B-box changes studied here.

The B-box 2 alterations decrease the capsid-binding abilities of TRIM5 α

TRIM5 α variants from Old World monkeys specifically associate with HIV-1 capsid complexes; this interaction depends on the TRIM5 α B30.2 domain (Stremlau et al., 2006). Human and New World monkey TRIM5 α proteins associate less efficiently with HIV-1 capsid complexes, accounting for the lack of HIV-1 restriction in cells of these species (Stremlau et al., 2006; Li et al., 2006c). Because the B-box 2 changes in this study affected TRIM5 α restriction activity in a potency-dependent manner determined by the B30.2 domain, the B-box 2 changes might affect the capsid-binding abilities of TRIM5 α . To test this hypothesis, a previously established *in vitro* HIV-1 CA-NC binding assay was employed (Li et al., 2006c; Stremlau et al., 2006). As expected (Li et al., 2006c; Stremlau et al., 2006), TRIM5 α_{rh} associated with the *in vitro* assembled HIV-1 CA-NC complexes efficiently; TRIM5 α_{hu} only weakly associated with the complexes (Figure 5). TRIM5 α H(R286-493), which has a B30.2 domain from TRIM5 α_{rh} , associated with the HIV-1 capsid complexes as efficiently as the wild-type TRIM5 α_{rh} . Conversely, TRIM5 α R(H286-493), with the B30.2 domain of TRIM5 α_{hu} , bound the HIV-1 capsid complexes inefficiently. To our surprise, both sets of B-box 2 alterations dramatically reduced the binding capabilities of TRIM5 α_{rh} , TRIM5 α H(R286-493)

and TRIM5 α_{hu} . The Cluster I-A and Cluster II-A changes did not cause any perceptible reduction in the binding of TRIM5 α R(H286-493) to HIV-1 CA-NC complexes, possibly due to the low binding level seen for the unmodified TRIM5 α R(H286-493) protein and the sensitivity of this assay. These results indicate that the Cluster I-A and Cluster II-A changes in the B-box 2 domain generally affect the capsid-binding affinity of TRIM5 α proteins.

The B-box 2 alterations do not affect trimerization and subcellular localization of TRIM5 α

On the linear sequence of TRIM5 α the B-box 2 domain is separated from the B30.2 domain by the coiled coil. One possible explanation for how changes in the B-box 2 domain could affect capsid binding is that the B-box 2 domain may be required to correctly orient the coiled-coil domain for trimerization, which in turn increases the avidity of TRIM5 α for retroviral capsids (Javanbakht et al., 2006). To evaluate this possibility, TRIM5 α_{rh} and TRIM5 α H (R286-493) and their derived B-box 2 mutants were subjected to crosslinking with glutaraldehyde. As shown in Figure 6, the Cluster I-A and Cluster II-A B-box 2 alterations do not significantly affect the ability of TRIM5 α proteins to trimerize.

Deletions or alterations of the TRIM5 α RING and B-box 2 domains are in some cases associated with changes in the subcellular localization of the mutant protein (Diaz-Griffero et al., 2006a; Diaz-Griffero et al., 2006b; Javanbakht et al., 2005; Reymond et al., 2001). However, neither of the B-box 2 alterations studied here caused redistribution of the TRIM5 α proteins (Figure 7). Within the limits of our ability to detect, the subcellular localization of the Cluster I-A and Cluster II-A mutants exhibited cytoplasmic localizations similar to those of the parental TRIM5 α variants.

Phenotype of B-box 2 changes in owl monkey TRIMCyp

A retrotransposition that occurred near the root of the owl monkey lineage of New World monkeys resulted in a replacement of the *TRIM5* gene with *TRIMCyp* (Nisole et al., 2004; Ribeiro et al., 2005; Sayah et al., 2004). The encoded TRIMCyp protein consists of a fusion of the RING, B-box 2 and coiled coil of TRIM5 with cyclophilin A. Because cyclophilin A interacts with the capsid proteins of HIV-1 and at least a few other retroviruses (Franke, Yuan, and Luban, 1994; Gamble et al., 1996; Lin and Emerman, 2006; Yoo et al., 1997), TRIMCyp can restrict infection by these viruses (Diaz-Griffero et al., 2006b; Nisole et al., 2004; Sayah et al., 2004; Zhang et al., 2006). Because cyclophilin A can bind with low affinity to monomeric HIV-1 capsid proteins (Yoo et al., 1997), the interaction of TRIMCyp with retroviral capsids may be less sensitive to B-box 2 changes than TRIM5 α -capsid interaction. To test this hypothesis, the abilities of wild-type TRIMCyp and B-box 2 Cluster I-A and Cluster II-A mutants to bind HIV-1 CA-NC complexes were compared. Figure 8A shows that neither of the B-box 2 alterations detectably affected the binding affinity of TRIMCyp for the assembled HIV-1 capsid complexes.

The effect of the Cluster I-A and Cluster II-A changes in the TRIMCyp B-box 2 domain on the ability to restrict HIV-1 infection was examined. The B-box 2 TRIMCyp mutants blocked HIV-1 infection nearly as efficiently as wild-type TRIMCyp (Figure 8B). None of the TRIMCyp variants inhibited N-MLV infection, as expected from the inability of cyclophilin A to interact with MLV capsids (Braaten, Franke, and Luban, 1996). We conclude that the Cluster I-A and Cluster II-A alterations do not appreciably affect TRIMCyp capsid interaction or antiviral activity.

Phenotype of B-box 2 changes in the context of a TRIM5-Cyp chimera

The different phenotypes associated with the Cluster I-A and Cluster II-A B-box 2 changes in the contexts of TRIM5 α and TRIMCyp proteins could formally be attributed to the use of cyclophilin A to bind the retroviral capsid or to the differences between the TRIM domains of

TRIM5 α and TRIMCyp. To distinguish these possibilities, we created and tested rhRBCC-Cyp, in which the cyclophilin A domain from owl monkey TRIMCyp replaces the B30.2 (SPRY) domain of TRIM5 α_{rh} (Figure 1). The Cluster I-A and Cluster II-A B-box 2 changes were introduced into the rhRBCC-Cyp protein. These B-box 2 changes did not affect the ability of the rhRBCC-Cyp protein to bind HIV-1 CA-NC complexes (Figure 9A). The abilities of the rhRBCC-Cyp Cluster I-A and Cluster II-A mutants to restrict HIV-1 infection were as great as that of the unmodified rhRBCC-Cyp protein (Figure 9B). The rhRBCC-Cyp proteins did not efficiently inhibit N-MLV infection (Figure 9C). We conclude that the Cluster I-A and Cluster II-A B-box 2 changes do not affect capsid binding and HIV-1 restriction when the capsid-binding moiety is cyclophilin A.

Discussion

Changes in the B-box 2 domains of TRIM5 α and TRIMCyp proteins have been shown to diminish or abolish antiretroviral activity (Diaz-Griffero et al., 2006b; Javanbakht et al., 2005; Li et al., 2006b; Perez-Caballero et al., 2005a). Some of these changes do not appreciably decrease expression levels, alter subcellular localization or affect the capsid-binding ability of the TRIM5 α /TRIMCyp proteins (Diaz-Griffero et al., 2006b; Stremlau et al., 2006). These B-box 2 changes apparently influence an “effector” function of TRIM5 α /TRIMCyp that operates after capsid binding. The nature of this effector function is not known; it may be involved in the accelerated uncoating of the retroviral capsid that is strongly correlated with TRIM5 α restriction of viral infection (Perron et al., 2006; Stremlau et al., 2006).

Here we studied two clusters (Cluster I-A and Cluster II-A) of TRIM5 α B-box 2 changes involving residues that differ between TRIM5 and the distant relative TRIM21. The TRIM21 B-box 2 domain very inefficiently substitutes for that of TRIM5 α , compared with the B-box 2 domains of the closer TRIM5 relatives, TRIM6 and TRIM34 (Li et al., 2006b). On models of the B-box 2 domain based upon the TRIM29 B-box 2 structure, most of the residues involved in the Cluster I-A and Cluster II-A changes are predicted to be surface-exposed (data not shown). A key observation of our studies is that the viral restriction phenotypes of the Cluster I-A and Cluster II-A B-box 2 mutants of TRIM5 α are conditional, influenced by both the TRIM5 α background and the restricted virus. The phenotypes of the B-box 2 mutants are generally correlated with the potency of the restriction against the particular viruses by the TRIM5 α parent with unmodified B-box 2 sequences. By analyzing recombinant TRIM5 α proteins, we show that the determinant of the conditional B-box 2 phenotype is the TRIM5 α B30.2 (SPRY) domain, which makes major contributions to capsid binding (Stremlau et al., 2006). Direct analysis of binding to HIV-1 capsid-nucleocapsid complexes revealed the surprising finding that both Cluster I-A and Cluster II-A B-box changes caused substantial reductions in capsid-binding affinity of TRIM5 α proteins. These results indicate that the decreases in TRIM5 α antiretroviral function associated with the Cluster I-A and Cluster II-A changes, by definition, do not result from disruption of an effector function. This conclusion is consistent with the expectation that TRIM5 α mutants with true effector function defects will exhibit a restriction phenotype regardless of the high affinity of TRIM5 α for the capsid, as has been previously observed (Diaz-Griffero et al., 2006b; Stremlau et al., 2006).

We considered several possible explanations for the unexpected effect of the Cluster I-A and Cluster II-A B-box 2 changes on TRIM5 α binding to the retroviral capsid:

1. Because TRIM5 α trimerization contributes greatly to the avidity for assembled HIV-1 capsid complexes (Javanbakht et al., 2006) and because of the proximity of the B-box 2 and coiled-coil domains, it is possible that the alterations introduced into the B-box 2 domain affected TRIM5 α trimer formation or stability. However, we observed no differences in trimerization between the TRIM5 α proteins with and without Cluster I-A and Cluster II-A changes.

2. The Cluster I-A and Cluster II-A changes could hypothetically disrupt B-box 2 contributions to capsid-binding affinity that are mediated by B-box 2-capsid contacts or by B-box 2 interactions with cellular cofactors that promote higher avidity. However, such models are incompatible with previous observations that the TRIM5 α B-box 2 domain can be disrupted or deleted with no apparent decrease in capsid-binding affinity (Stremlau et al., 2006).
3. The Cluster I-A and Cluster II-A B-box 2 changes might alter capsid-binding avidity by influencing the orientation of the B30.2(SPRY) domains. The available data are compatible with this explanation. In particular, our observations with TRIMCyp and rh5RBCC-Cyp mutants indicate the specificity of the effects of these B-box 2 changes for TRIM5 proteins with B30.2(SPRY) domains. The Cluster I-A and Cluster II-A B-box 2 changes exerted no detectable effect on the ability of TRIMCyp or rh5RBCC-Cyp to bind HIV-1 capsid complexes. In the TRIMCyp and rh5RBCC-Cyp proteins, the capsid-binding moiety of TRIM5 α , the B30.2(SPRY) domain, is replaced by cyclophilin A. Thus, the disruptive effects of the Cluster I-A and Cluster II-A B-box 2 changes on HIV-1 capsid binding are apparently dependent on the B30.2(SPRY) domains being the direct capsid-binding entity; these disruptive effects are completely eliminated when the capsid recognition function is mediated by the cyclophilin A domain. These observations support a model in which the B-box 2 and B30.2 domains are spatially related on TRIM5 α proteins. Presumably the spatial relationships and potential packing contacts involving the B-box 2 and B30.2(SPRY) domains on the TRIM5 α trimer differ from those of the B-box 2 and cyclophilin A domains on the TRIMCyp trimer. Thus, in this model, the effects of Cluster I-A and Cluster II-A B-box 2 changes on capsid binding are expected to differ for TRIM5 α and TRIMCyp proteins.

The observed effects of the Cluster I-A and Cluster II-A B-box 2 changes on capsid binding could be mediated by direct B-box 2 - B30.2(SPRY) contacts or by indirect alteration of subunit relationships on the trimer. Precise understanding of these relationships awaits a TRIM5 α structure.

We note that the binding of the Cluster I-A B-box 2 mutants to HIV-1 CA-NC complexes was generally very low, and did not demonstrate an increase even for TRIM5 α proteins (TRIM5 α_{rh} (I) and TRIM5 α H(R286-493) (I)) that exhibited HIV-1-restricting ability. These observations suggest that, at least for TRIM5 α proteins like the Cluster I-A mutants whose level of expression is low, the HIV-1 capsid-binding assay is not sensitive enough to allow precise assessment of affinities that, although low, can still influence biological phenotypes.

Although replacement of the TRIM5 α_{hu} B30.2(SPRY) domain with the complete B30.2 (SPRY) domain of TRIM5 α_{rh} reverted the HIV-1-restriction phenotype of the Cluster I-A and Cluster II-A B-box 2 changes, the replacement of arginine 332 in the B30.2(SPRY) domain did not. This is consistent with previous observations suggesting that, although the presence of arginine at residue 332 is the major determinant of the poor anti-HIV-1 potency of TRIM5 α_{hu} , its replacement is not sufficient to achieve the same levels of HIV-1 capsid binding and restriction as those of TRIM5 α_{rh} (Li et al., 2006c). Thus, TRIM5 α_{hu} R332P has apparently gained sufficient affinity for the HIV-1 (and possibly SIV_{mac}) capsids to allow restriction, but not enough to counteract the influence of these particular B-box 2 alterations.

Further studies of TRIM5 α and TRIMCyp may provide an understanding of the structural basis of the functional inter-domain relationships elucidated in this work.

Materials and Methods

Plasmid construction

Mutations affecting the B-box 2 domain of the wild-type human and rhesus monkey TRIM5 α proteins were introduced into pLPCX-TRIM5 α expression plasmids, using overlapping PCR extension with primers carrying the corresponding nucleic acid changes (Horton et al., 1993; Horton et al., 1989). The PCR-amplified TRIM5 fragments were digested and cloned into the *EcoRI* and *ClaI* sites of the pLPCX vector, as previously described (Stremlau et al., 2004). The chimeric constructs containing B-box 2 alterations were created by exchanging fragments generated by *BsmI* and *ClaI* digestion of the above constructs and similarly digested plasmids expressing TRIM5 α R(H286-493), TRIM5 α H(R286-493), TRIM5 α_{hu} R332P or TRIMCyp (Stremlau et al., 2005). The rh5RBCC-Cyp protein contains residues 1-296 of TRIM5 α_{rh} (MASGIL...FRELTD²⁹⁶) fused to the Cyp A domain from owl monkey TRIMCyp. The junction of the TRIM5 α_{rh} and TRIMCyp moieties in the rh5RBCC-Cyp has the following sequence: ...FRELTD²⁹⁶AQRYWDAAAWDLVASAMVNPTV... All constructs contain C-terminal epitope tags derived from influenza hemagglutinin (HA).

Creation of cells stably expressing TRIM proteins

Recombinant viruses were produced in 293FT cells (Invitrogen) by cotransfecting the pLPCX plasmids expressing TRIM proteins with the pVPack-GP and pVPack-VSV-G packaging plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the vesicular stomatitis virus (VSV) G envelope glycoprotein, which allows efficient entry into a wide range of vertebrate cells (Yee, Friedmann, and Burns, 1994). The resulting virus particles were used to transduce 2×10^5 HeLa cells in six-well plates. The transduced HeLa cells were then selected in 1 $\mu\text{g}/\text{ml}$ puromycin (Sigma).

Immunoblotting

HeLa cells stably expressing the transduced proteins were lysed with phosphate-buffered saline (2.7 mM KCl, 1.5 mM KH₂PO₄, 138 mM NaCl, 8 mM Na₂PO₄) containing 1% NP40 and protease inhibitor cocktail (Roche). The lysates were resolved by SDS-PAGE and Western blotted with horseradish peroxidase (HRP)-conjugated anti-HA antibody (Roche) and anti- β -actin antibody (Sigma).

Infection with viruses expressing GFP

Recombinant HIV-1, SIV_{mac}, and N-MLV viruses expressing green fluorescent protein (GFP) were made as previously described (Perron et al., 2004; Stremlau et al., 2004). For infection, 3×10^4 cells were seeded in 24-well plates and incubated with the viruses for 60 hours. Cells were then washed with PBS, fixed with 3.7% formaldehyde and subjected to fluorescence-activated cell sorting (FACS) analysis with a FACScan (Becton Dickinson).

Crosslinking of TRIM proteins

Cell lysates prepared in 1% NP40/PBS/protease inhibitor cocktail were incubated with varying concentrations (final concentration: 0, 0.2, 0.4, 0.8 and 2.0 mM) of glutaraldehyde (Sigma) at room temperature for 5 minutes, followed by adding excess glycine to quench the reaction. The crosslinked lysates were then subjected to SDS-PAGE and Western blotted with HRP-conjugated anti-HA antibody (Roche).

Subcellular localization using immunofluorescence confocal microscopy

HeLa cells stably expressing TRIM5 α variants were cultured on 8-well chamber slides. Twenty-four hours later, the cells were fixed, permeabilized, and incubated with rat anti-HA 3F10 antibody (1:200, Roche) followed by secondary anti-rat IgG conjugated with FITC

(1:200, Santa Cruz). The processed cells were analyzed using a confocal microscope (Nikon Eclipse E800) with laser (Bio-Rad MRC 1024), and the images were obtained using Bio-Rad Lasersharp 2000 software.

HIV-1 capsid-binding assay

Purification of recombinant HIV-1 CA-NC protein from *Escherichia coli* was carried out as previously described (Ganser et al., 1999). For a source of TRIM5 proteins, HeLa cells stably expressing the TRIM5 variants were lysed by freeze-thawing in hypotonic lysis buffer (10 mM Tris, pH 7.4, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT) containing protease inhibitor (Roche). The lysates were then mixed with the *in vitro* assembled HIV-1 CA-NC complexes and the binding assay was carried out as previously described (Li et al., 2006a; Li et al., 2006c; Stremlau et al., 2006).

Acknowledgments

We thank Ms. Yvette McLaughlin and Ms. Elizabeth Carpelan for manuscript preparation and the National Institutes of Health (AI063987 and a Center for AIDS Research Award AI06354), the International AIDS Vaccine Initiative, the Bristol-Myers Squibb Foundation, and the late William F. McCarty-Cooper.

References

- Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, Hope TJ. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. *J Virol* 2006;80(19):9754–60. [PubMed: 16973579]
- Best S, Le Tissier P, Towers G, Stoye JP. Positional cloning of the mouse retrovirus restriction gene Fv1. *Nature* 1996;382(6594):826–9. [PubMed: 8752279]
- Braaten D, Franke EK, Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. *J Virol* 1996;70(7):4220–7. [PubMed: 8676442]
- Cao T, Borden KL, Freemont PS, Etkin LD. Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution. *J Cell Sci* 1997;110(Pt 14):1563–71. [PubMed: 9247190]
- Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, Sodroski J. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. *Virology*. 2006a
- Diaz-Griffero F, Vandegraaff N, Li Y, McGee-Estrada K, Stremlau M, Welikala S, Si Z, Engelman A, Sodroski J. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. *Virology* 2006b;351(2):404–19. [PubMed: 16650449]
- Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, Piccolo S. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. *Cell* 2005;121(1):87–99. [PubMed: 15820681]
- Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. *J Virol* 2002;76(11):5667–77. [PubMed: 11991995]
- Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. *Nature* 1994;372(6504):359–62. [PubMed: 7969494]
- Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. *Cell* 1996;87(7):1285–94. [PubMed: 8980234]
- Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI. Assembly and analysis of conical models for the HIV-1 core. *Science* 1999;283(5398):80–3. [PubMed: 9872746]
- Hartley JW, Rowe WP, Huebner RJ. Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. *J Virol* 1970;5(2):221–5. [PubMed: 4317349]

- Hatzioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. *Proc Natl Acad Sci U S A* 2004;101(29):10774–9. [PubMed: 15249685]
- Horn EJ, Albor A, Liu Y, El-Hizawi S, Vanderbeek GE, Babcock M, Bowden GT, Hennings H, Lozano G, Weinberg WC, Kulesz-Martin M. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. *Carcinogenesis* 2004;25(2):157–67. [PubMed: 14578165]
- Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease LR. Gene splicing by overlap extension. *Methods Enzymol* 1993;217:270–9. [PubMed: 8474334]
- Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. *Gene* 1989;77(1):61–8. [PubMed: 2744488]
- Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. *J Biol Chem* 2005;280(29):26933–40. [PubMed: 15897199]
- Javanbakht H, Yuan W, Yeung DF, Song B, Diaz-Griffero F, Li Y, Li X, Stremlau M, Sodroski J. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. *Virology* 2006;353(1):234–46. [PubMed: 16808955]
- Keckesova Z, Ylinen LM, Towers GJ. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. *Proc Natl Acad Sci U S A* 2004;101(29):10780–5. [PubMed: 15249687]
- Li X, Gold B, O'Huigin C, Diaz-Griffero F, Song B, Si Z, Li Y, Yuan W, Stremlau M, Mische C, Javanbakht H, Scally M, Winkler C, Dean M, Sodroski J. Unique features of TRIM5alpha among closely related human TRIM family members. *Virology*. 2006a
- Li X, Li Y, Stremlau M, Yuan W, Song B, Perron M, Sodroski J. Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. *J Virol* 2006b;80(13):6198–206. [PubMed: 16775307]
- Li Y, Li X, Stremlau M, Lee M, Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. *J Virol* 2006c;80(14):6738–44. [PubMed: 16809279]
- Lilly F. Susceptibility to two strains of Friend leukemia virus in mice. *Science* 1967;155(761):461–2. [PubMed: 6015694]
- Lilly F. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. *J Natl Cancer Inst* 1970;45(1):163–9. [PubMed: 5449211]
- Lin TY, Emerman M. Cyclophilin A interacts with diverse lentiviral capsids. *Retrovirology* 2006;3:70. [PubMed: 17038183]
- Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. *Bioessays* 2005;27(11):1147–57. [PubMed: 16237670]
- Mische CC, Javanbakht H, Song B, Diaz-Griffero F, Stremlau M, Strack B, Si Z, Sodroski J. Retroviral restriction factor TRIM5alpha is a trimer. *J Virol* 2005;79(22):14446–50. [PubMed: 16254380]
- Nisole S, Lynch C, Stoye JP, Yap MW. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. *Proc Natl Acad Sci U S A* 2004;101(36):13324–8. [PubMed: 15326303]
- Perez-Caballero D, Hatzioannou T, Yang A, Cowan S, Bieniasz PD. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. *J Virol* 2005a;79(14):8969–78. [PubMed: 15994791]
- Perez-Caballero D, Hatzioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. *J Virol* 2005b;79(24):15567–72. [PubMed: 16306627]
- Perron MJ, Stremlau M, Lee M, Javanbakht H, Sodroski J. The Human TRIM5{alpha} Restriction Factor Mediates Accelerated Uncoating of the N-tropic Murine Leukemia Virus Capsid. *J Virol*. 2006
- Perron MJ, Stremlau M, Sodroski J. Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. *J Virol* 2006;80(11):5631–6. [PubMed: 16699044]

- Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. *Proc Natl Acad Sci U S A* 2004;101(32):11827–32. [PubMed: 15280539]
- Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A. The tripartite motif family identifies cell compartments. *EMBO J* 2001;20(9):2140–51. [PubMed: 11331580]
- Ribeiro IP, Menezes AN, Moreira MA, Bonvicino CR, Seuanez HN, Soares MA. Evolution of cyclophilin A and TRIMCyp retrotransposition in New World primates. *J Virol* 2005;79(23):14998–5003. [PubMed: 16282502]
- Sayah DM, Sokolskaja E, Berthou L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. *Nature* 2004;430(6999):569–73. [PubMed: 15243629]
- Sebastian S, Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. *Retrovirology* 2005;2:40. [PubMed: 15967037]
- Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* 2002;418(6898):646–50. [PubMed: 12167863]
- Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. *Nature* 2004;427(6977):848–53. [PubMed: 14985764]
- Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. *Proc Natl Acad Sci U S A* 2006;103(14):5514–9. [PubMed: 16540544]
- Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. *J Virol* 2005;79(5):3139–45. [PubMed: 15709033]
- Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, Ropers HH, Schneider R, Schweiger S. MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. *Nat Genet* 2001;29(3):287–94. [PubMed: 11685209]
- Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. *Proc Natl Acad Sci U S A* 2006;103(19):7465–70. [PubMed: 16648264]
- Xu L, Yang L, Moitra PK, Hashimoto K, Rallabhandi P, Kaul S, Meroni G, Jensen JP, Weissman AM, D'Arpa P. BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta. *Exp Cell Res* 2003;288(1):84–93. [PubMed: 12878161]
- Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. *Proc Natl Acad Sci U S A* 2004;101(29):10786–91. [PubMed: 15249690]
- Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. *Curr Biol* 2005;15(1):73–8. [PubMed: 15649369]
- Yee JK, Friedmann T, Burns JC. Generation of high-titer pseudotyped retroviral vectors with very broad host range. *Methods Cell Biol* 1994;43(Pt A):99–112. [PubMed: 7823872]
- Yoo S, Myszka DG, Yeh C, McMurray M, Hill CP, Sundquist WI. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. *J Mol Biol* 1997;269(5):780–95. [PubMed: 9223641]
- Zhang F, Hatzioannou T, Perez-Caballero D, Derse D, Bieniasz PD. Antiretroviral potential of human tripartite motif-5 and related proteins. *Virology* 2006;353(2):396–409. [PubMed: 16828831]




Figure 1. TRIM5 and TRIMCyp constructs

The human and rhesus monkey TRIM5 α proteins, TRIM5 α_{hu} and TRIM5 α_{rh} chimeric proteins, and the owl monkey TRIMCyp protein are depicted. A chimeric rh5RBCC-Cyp protein in which the amino-terminal portion of TRIM5 α_{rh} was fused with the cyclophilin A domain of owl monkey TRIMCyp was also studied. The changes introduced into the B-box 2 domain of the proteins to create the Cluster I-A and II-A mutants are shown. The carboxy-terminal HA tag is shown.




Figure 2. Expression and antiretroviral activity of TRIM5αB-box 2 mutants

(A). The expression level of TRIM5α proteins with C-terminal HA tags in HeLa cells stably expressing these proteins was determined by Western blotting comparable amounts of cell lysate with an anti-HA antibody. The blot was also probed for β-actin to control for loading amount. Rh5, wild-type rhesus monkey TRIM5α; hu5, wild-type human TRIM5α; the mutants labeled X(I) contain the Cluster I-A B-box 2 domain changes Q109E, E110K, V114A, I115L and L118V; the mutants labeled X(II) contain the Cluster II-A B-box 2 domain changes E120A, R121Q, Q123R and E124K, where X represents the TRIM5 backbone (X = rh5, rhesus monkey TRIM5α; X = hu5, human TRIM5α) in which the changes were made. (B). The effects of the TRIM5α proteins described above on retroviral infection were assessed. HeLa cells stably expressing the wild-type and mutant TRIM proteins, or control HeLa cells transduced with the empty LPCX vector, were incubated with various amounts of HIV-1-GFP or N-MLV-GFP. Infected GFP-positive cells were counted by FACS. Twenty microliters of the preparation of HIV-1-GFP used in these experiments correspond to ~3,000 cpm reverse transcriptase units; 100 microliters of N-MLV-GFP correspond to ~400 cpm reverse transcriptase units.




Figure 3. Expression and antiretroviral activity of TRIM5 α_{rh} -TRIM5 α_{hu} chimerae with B-box 2 changes

(A). Expression of the unmodified (wt) TRIM5 α R(H286-493) and H(R286-493) proteins and the Cluster I-A (I) and Cluster II-A (II) mutants was examined by Western blotting lysates from HeLa cells with an anti-HA antibody (Roche). Lysates were Western blotted for β -actin as a control. Rh5 = wild-type TRIM5 α_{rh} . (B). Infection with HIV-1-GFP and N-MLV-GFP of HeLa cell lines stably expressing the indicated parental and mutant proteins. The results shown are typical of those obtained in two repeat experiments. (rh5 = TRIM5 α_{rh} ; hu = TRIM5 α_{hu}).




Figure 4. Effects of B-box 2 domain changes on the antiretroviral activity of human TRIM5 α R332P (A). Expression of the mutant proteins in HeLa cells was analyzed by Western blotting, as described in the Figure 1 legend. Lysates were also blotted with an antibody against β -actin as a control. (hu5 R332P = TRIM5 α _{hu} R332P). **(B and C).** HeLa cells expressing the indicated proteins were incubated with HIV-1-GFP and SIVmac-GFP **(B)** and N-MLV-GFP **(C)**, then analyzed for GFP expression by FACS. Ten dose units of this preparation of SIV_{mac} correspond to ~3000 cpm reverse transcriptase units. The experiment was repeated twice with results similar to those shown.




Figure 5. Effects of the B-box 2 changes on the association of TRIM5 proteins with assembled HIV-1 capsid complexes

Cell lysates of HeLa cells stably expressing the C-terminally HA-tagged TRIM5 variants were used in the HIV-1 CA-NC binding assay. The top and middle panels show the amounts of TRIM5 protein in the input and pellet, respectively; the bottom panel shows the amount of HIV-1 CA-NC protein that was pelleted through the 70% sucrose cushion. None of the TRIM5 protein variants were able to pellet through the 70% sucrose cushion in the absence of added HIV-1 CA-NC complexes (data not shown). (hu5 = human TRIM5 α ; rh5 = TRIM5 α_{rh} ; wt = wild-type; I = Cluster I-A mutant; II = Cluster II-A mutant).




Figure 6. Oligomerization of TRIM5 α protein variants

Lysates from HeLa cells stably expressing the indicated TRIM5 α proteins were crosslinked with increasing concentrations of glutaraldehyde (0, 0.2, 0.4, 0.8 and 2.0 mM). The crosslinked products were resolved by SDS-PAGE and visualized by Western blotting with an anti-HA antibody. The position of the molecular weight markers is indicated on the figure.




Figure 7. Localization of TRIM5 α protein variants

HeLa cells stably expressing the indicated HA-tagged TRIM5 α proteins (or the empty LPCX vector) were fixed and permeabilized. Cells were stained with an anti-HA antibody followed by a secondary anti-rat IgG antibody conjugated with FITC. Stained cells were examined using a confocal fluorescent microscope. The unmodified TRIM5 α proteins (wt) are shown in the left column, and the Cluster I-A and Cluster II-A variants of each protein in the middle and right columns, respectively.




Figure 8. Effects of B-box 2 changes on TRIMCyp function

(A). The indicated TRIM5 α and TRIMCyp variants were expressed stably in HeLa cells. Cell lysates were incubated with HIV-1 CA-NC complexes and the mixtures were layered onto a 70% sucrose cushion and centrifuged. The TRIM5 α and TRIMCyp proteins in the input and pellet were detected by Western blotting with an anti-HA antibody. The CA-NC protein in the pellet was detected by Western blotting with an anti-p24 antibody. (B and C). HeLa cells stably expressing the indicated TRIM5 α or TRIMCyp variants were exposed to the indicated amounts of HIV-1-GFP (B) or N-MLV-GFP (C). GFP-positive cells were counted. The results shown are those of a typical experiment; the experiment was repeated with similar results.




Figure 9. Effects of B-box 2 changes on the chimeric rh5RBCC-Cyp protein

(A) The binding of the unmodified rh5RBCC-Cyp (wt) protein and the Cluster I-A (I) and Cluster II-A (II) derivatives to HIV-1 CA-NC complexes was assessed on 70% sucrose cushions. TRIM5 α_{rh} (rh5) and TRIM5 α_{hu} (hu 5) were included as controls. The steady-state expression level of the unmodified (wt) rhRBCC-Cyp protein was significantly lower than that of TRIM5 α_{rh} , and the Cluster I-A and II-A derivatives of rh5RBCC-Cyp were expressed at approximately 5-fold higher levels than that of the wt rhRBCC-Cyp protein (data not shown). In the binding assay, an attempt was made to adjust the amount of input lysate to offset these different levels of expression. The TRIM5 proteins were detected by Western blotting with an anti-HA antibody, and the CA-NC protein by an anti-p24 antibody. (B and C) HeLa cells

stably expressing the indicated proteins were exposed to HIV-1-GFP (**B**) or N-MLV-GFP (**C**). GFP-positive cells were counted. The results of typical experiments are shown.